Answers are grounded in this paper and cite their sources.
The burden of cutaneous malignant melanoma (CMM) varies widely across populations. Accurate burden assessment is critical for refining public health strategies. This study aimed to analyze the temporal trends in CMM burden among adults aged greater than or equal to 65 years in East Asia from 1990 to 2023 and to project the future burden up to 2050. Using the Global Burden of Disease Study 2023 data, we estimated the age-standardized incidence, prevalence, and mortality rates and their estimated annual percentage changes (EAPCs) for CMM across six GBD locations representing five countries: Japan, South Korea, North Korea, Mongolia, and China (comprising two locations: the Chinese mainland and Taiwan Province of China). A Bayesian age–period–cohort model projected trends to 2050. CMM burden increased strongly with age and varied by sex. Between 1990 and 2023, the most pronounced increases in age-standardized incidence and prevalence rates were observed in South Korea (EAPC = 4.33 and 7.31, respectively), whereas North Korea had the largest increase in the age-standardized mortality rate (EAPC = 1.37). From 2024 to 2050, age-standardized incidence is projected to increase in all study populations except Mongolia, whereas age-standardized prevalence is projected to increase in all populations. In 2050, South Korea is projected to have the highest age-standardized incidence and prevalence rates (21.51 and 238.24 per 100 000, respectively), and North Korea the highest age-standardized mortality rate (3.38 per 100 000). These findings characterize the evolving CMM burden among older adults in East Asia and may inform age- and sex-specific prevention strategies and resource allocation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: